![Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial - European Journal of Cancer Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial - European Journal of Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/a8d1116f-d1fb-4353-aaf4-b8513d7fe74f/gr3a_lrg.jpg)
Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial - European Journal of Cancer
![Medicines | Free Full-Text | The Changing Landscape of Breast Cancer: How Biology Drives Therapy | HTML Medicines | Free Full-Text | The Changing Landscape of Breast Cancer: How Biology Drives Therapy | HTML](https://www.mdpi.com/medicines/medicines-03-00002/article_deploy/html/images/medicines-03-00002-g001.png)
Medicines | Free Full-Text | The Changing Landscape of Breast Cancer: How Biology Drives Therapy | HTML
![Lapatinib plus Capecitabine versus Trastuzumab plus Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer with Central Nervous System Metastases for Patients Currently or Previously Treated with Lapatinib plus Capecitabine versus Trastuzumab plus Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer with Central Nervous System Metastases for Patients Currently or Previously Treated with](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/a51251fb-853f-47b5-81f0-367580b1bee7/gr1_lrg.jpg)
Lapatinib plus Capecitabine versus Trastuzumab plus Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer with Central Nervous System Metastases for Patients Currently or Previously Treated with
![T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study - ESMO Open T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study - ESMO Open](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/7a5f26b4-c209-4ebe-a035-033406e4a538/gr1_lrg.jpg)
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study - ESMO Open
![CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer. | Semantic Scholar CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/dc2e054b442af535f20fa983929a0f46b3452c87/2-Table1-1.png)
CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer. | Semantic Scholar
![Summary of the CLEOPATRA, APHINITY, NeoSphere, and TRYPHAENA clinical... | Download Scientific Diagram Summary of the CLEOPATRA, APHINITY, NeoSphere, and TRYPHAENA clinical... | Download Scientific Diagram](https://www.researchgate.net/publication/336920151/figure/tbl1/AS:820051573735424@1572526939433/Summary-of-the-CLEOPATRA-APHINITY-NeoSphere-and-TRYPHAENA-clinical-trials.png)
Summary of the CLEOPATRA, APHINITY, NeoSphere, and TRYPHAENA clinical... | Download Scientific Diagram
![Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. | Semantic Scholar Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/bedf0b307bcd2706ba7837cb76dd60ae0bb44741/2-Figure1-1.png)
Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. | Semantic Scholar
![Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study - The Lancet Oncology Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/907376aa-9756-4c9e-82b3-b2f6b5e0dd1a/gr2.jpg)
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study - The Lancet Oncology
![Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial - European Journal of Cancer Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial - European Journal of Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/59730514-b6f5-4233-92a4-d3359fe836fc/gr1.jpg)
Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial - European Journal of Cancer
![Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer - Annals of Oncology Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/95f59ef1-cdc5-49a8-a205-50cb8b8aa4ef/gr1_lrg.jpg)
Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer - Annals of Oncology
![Expert Guidance on Selecting Treatment and Management Approaches in Metastatic Breast Cancer Jointly sponsored by the Annenberg Center for Health Sciences. - ppt download Expert Guidance on Selecting Treatment and Management Approaches in Metastatic Breast Cancer Jointly sponsored by the Annenberg Center for Health Sciences. - ppt download](https://images.slideplayer.com/37/10719684/slides/slide_37.jpg)
Expert Guidance on Selecting Treatment and Management Approaches in Metastatic Breast Cancer Jointly sponsored by the Annenberg Center for Health Sciences. - ppt download
![Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study - The Lancet Oncology Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/4da2f12b-83e5-4a0d-876b-2a682f415377/gr2.jpg)
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study - The Lancet Oncology
![Pertuzumab with Trastuzumab and Docetaxel in Elderly Patients in the CLEOPATRA Study | Research To Practice Pertuzumab with Trastuzumab and Docetaxel in Elderly Patients in the CLEOPATRA Study | Research To Practice](http://www.researchtopractice.com/sites/default/files/imagecache/slideshow_image/5mjc/slides/2011/5MJCSABCS2013/2/2/Slide2.jpg)
Pertuzumab with Trastuzumab and Docetaxel in Elderly Patients in the CLEOPATRA Study | Research To Practice
![Summary of the CLEOPATRA, APHINITY, NeoSphere, and TRYPHAENA clinical... | Download Scientific Diagram Summary of the CLEOPATRA, APHINITY, NeoSphere, and TRYPHAENA clinical... | Download Scientific Diagram](https://www.researchgate.net/publication/336920151/figure/tbl1/AS:820051573735424@1572526939433/Summary-of-the-CLEOPATRA-APHINITY-NeoSphere-and-TRYPHAENA-clinical-trials_Q640.jpg)